Experimental CAR-T therapy takes on progressive MS

NCT ID NCT06138132

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells (B cells) that may drive MS. The study will enroll 12 adults aged 18-65 and primarily check for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KYV-101 CAR-T cell therapy (a personalized immune cell treatment) plus bendamustine (a chemotherapy drug to prepare the body)
What this could lead to: If successful, this could point toward a new way to slow or stop worsening disability in progressive multiple sclerosis by targeting faulty immune cells.
What could go wrong: This is a very early Phase 1 trial with only 12 people, focused on safety. The therapy may cause serious side effects like cytokine release syndrome or nerve problems, and it is not yet known if it will help the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS, SECONDARY PROGRESSIVE

Contacts and locations

Locations

Stanford Multiple Sclerosis Center
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.